Revised SPC: Tecentriq (atezolizumab) 840 mg concentrate for solution for infusion

The SPC has been updated to include currently available data on use in children and adolescents, and to state that no recommendations on a posology can be made. Details of an exploratory updated survival analysis of the IMvigor211 trial have also been added.


electronic Medicines compendium